GlassScriptPhysician profile
Jacinda Beth Sampson
NPI 1427000710
$3,770.43
in general payments reported to CMS, 2019-2025
8 companies · $473 in 2025
The $473 reported for 2025 was less than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
See the full distribution for Neuromuscular Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $60.00 · 2021: $65.16 · 2022: $121 · 2023: $2,960 · 2024: $91.60 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,216 · Food and Beverage: $293 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,216.00 |
| Food and Beverage | $293.03 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,922.94 | 2022-2023 | Spinraza |
| Vertex Pharmaceuticals Incorporated | $457.50 | 2025 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $142.71 | 2020-2023 | Zolgensma |
| Genentech, INC. | $140.68 | 2023 | Evrysdi |
| Novartis Pharmaceuticals Corporation | $91.60 | 2024 | |
| Ucb, INC. | $15.00 | 2025 | Rystiggo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacinda Sampson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.